Side-by-side · Research reference

OvagenvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BPhase 3HUMAN-REVIEWED25/54 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

Ovagen

Survodutide

Primary target

Ovarian tissue chromatin complexes

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

—

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

—

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

Survodutide

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Once weekly

Evidence basis

Theoretical / Russian-tradition

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

—

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

Ovagen

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

Ovagen

Survodutide

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

—

Long-term safety

Unknown — no PubMed-indexed RCTs

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

Ovagen

Survodutide

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

—

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.